Fibroblast growth factor 21 has been suggested as a promising new drug for treating diabetes and obesity thanks to its multiple metabolic-regulating functions, such as enhancing insulin sensitivity and increasing energy expenditure (7). Here, FGF21 is linked to obesity due to melanocortin 4 receptor deficiency.